Troxipide
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Troxipide: From Gastric Ulcer to esophagitis (disease)
One-Sentence Summary
Troxipide is a gastric cytoprotective agent, originally used to treat gastric ulcer. The TxGNN model predicts it may be effective for esophagitis, but no clinical trials and no publications currently support this specific indication, so the prediction rests on the computational model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gastric ulcer |
| Predicted New Indication | Esophagitis |
| TxGNN Prediction Score | 0.9994 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (3 of 3) – CDSCO approval status is not included in this data |
| Number of Listed Products | 3 (valid: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, troxipide is a gastric cytoprotective (mucosal-protective) agent, its use in gastric ulcer is established, and mechanistically it may be applicable to esophagitis.
Reported effects of troxipide include mucosal protection and inhibition of neutrophil migration and activation. Because neutrophil-driven inflammation and mucosal injury also feature in esophageal mucosal damage, an extension to esophagitis is plausible. Both conditions are inflammatory or erosive injuries of the upper gastrointestinal mucosa.
However, this remains a hypothesis. The very high TxGNN score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. No trials or publications specific to esophagitis were identified in the data compiled for this report.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for esophagitis.
For context, the literature found for other indications is entirely preclinical. It includes work on neutrophil inhibition (PMID 11515628) and rat gastric ulcer and mucosal lesion models (PMID 7959422, 8288208, 32788674). None of it involves esophagitis or human efficacy trials.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 215950 | Troxip Tablet (Zuventus Healthcare Ltd) | Strip of 10 tablets | Not specified |
| 221481 | Troxpro 100mg Tablet (Emcure Pharmaceuticals Ltd) | Strip of 10 tablets | Not specified |
| 215848 | Troxip-OD Tablet PR (Zuventus Healthcare Ltd) | Strip of 10 prolonged-release tablets | Not specified |
All three registrations are valid single-ingredient oral products.
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found for troxipide in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The esophagitis prediction has a very high model score but no supporting trials or literature (Evidence Level L5). Troxipide is already marketed in India, which lowers access barriers, but efficacy in esophagitis is unsupported.
To proceed, the following is needed:
- Mechanism of action data for troxipide
- Package insert warnings and contraindications from the Indian labels (including approved indication text)
- Preclinical or clinical studies of troxipide in esophagitis, such as reflux or erosive esophagitis models
- A literature search targeted at esophageal mucosal protection with troxipide
- Assessment of route and formulation suitability for esophageal exposure
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.